GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 2,075,177 shares, a growth of 243.3% from the April 30th total of 604,557 shares. Currently, 6.0% of the company’s shares are short sold. Based on an average daily volume of 2,320,983 shares, the short-interest ratio is presently 0.9 days.

GT Biopharma Stock Performance

NASDAQ:GTBP traded up $0.03 during trading hours on Friday, hitting $0.48. 3,445,841 shares of the company’s stock traded hands, compared to its average volume of 2,039,919. The firm has a market cap of $17.24 million, a P/E ratio of -0.08 and a beta of 0.64. GT Biopharma has a twelve month low of $0.26 and a twelve month high of $3.85. The stock’s fifty day moving average price is $0.40 and its two-hundred day moving average price is $0.55.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). On average, equities research analysts predict that GT Biopharma will post -0.34 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GT Biopharma in a research report on Friday, April 10th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, GT Biopharma currently has a consensus rating of “Sell”.

Institutional Trading of GT Biopharma

A hedge fund recently bought a new stake in GT Biopharma stock. SeaCrest Wealth Management LLC acquired a new stake in shares of GT Biopharma, Inc. (NASDAQ:GTBP) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned about 0.47% of GT Biopharma at the end of the most recent quarter. 8.15% of the stock is owned by hedge funds and other institutional investors.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).